IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

American Journal of Cardiovascular Drugs

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on June 27, 2025

Impact Score

2024-2025

2.80

h-Index

2024-2025

 63

Rank

2024-2025

 5925

SJR

2024-2025

 0.876

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title American Journal of Cardiovascular Drugs
Abbreviation Am. J. Cardiovasc. Drugs
Publication Type Journal
Subject Area, Categories, Scope Cardiology and Cardiovascular Medicine (Q2); Medicine (miscellaneous) (Q2); Pharmacology (medical) (Q2)
h-index 63
Overall Rank/Ranking 5925
SCImago Journal Rank (SJR) 0.876
Impact Score 2.80
Publisher
Country Switzerland
ISSN 11753277, 1179187X
Best Quartile Q2
Coverage History 2001-2025




About American Journal of Cardiovascular Drugs


American Journal of Cardiovascular Drugs is a journal covering the technologies/fields/categories related to Cardiology and Cardiovascular Medicine (Q2); Medicine (miscellaneous) (Q2); Pharmacology (medical) (Q2). It is published by . The overall rank of American Journal of Cardiovascular Drugs is 5925. According to SCImago Journal Rank (SJR), this journal is ranked 0.876. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 63. The best quartile for this journal is Q2.

The ISSN of American Journal of Cardiovascular Drugs journal is 11753277, 1179187X. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. American Journal of Cardiovascular Drugs is cited by a total of 525 articles during the last 3 years (Preceding 2024).


American Journal of Cardiovascular Drugs Impact IF 2024-2025


The Impact IF 2024 of American Journal of Cardiovascular Drugs is 2.80, which is computed in 2025 as per its definition. American Journal of Cardiovascular Drugs IF is increased by a factor of 0.14 and approximate percentage change is 5.26% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

American Journal of Cardiovascular Drugs Impact IF 2025 Prediction


Impact IF 2024 of American Journal of Cardiovascular Drugs is 2.80. If the same upward trend persists, Impact IF may rise in 2025 as well.


Impact IF Trend


Year wise Impact IF of American Journal of Cardiovascular Drugs. Based on Scopus data.


Year Impact IF
2025/2026 Coming Soon
2024 2.80
2023 2.66
2022 3.12
2021 3.56
2020 2.86
2019 2.60
2018 2.40
2017 2.85
2016 2.98
2015 2.49
2014 2.60

American Journal of Cardiovascular Drugs h-index


  Table Setting

American Journal of Cardiovascular Drugs has an h-index of 63. It means 63 articles of this journal have more than 63 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




American Journal of Cardiovascular Drugs ISSN


The ISSN of American Journal of Cardiovascular Drugs is 11753277, 1179187X. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

American Journal of Cardiovascular Drugs Rank and SCImago Journal Rank (SJR)


The overall rank of American Journal of Cardiovascular Drugs is 5925. According to SCImago Journal Rank (SJR), this journal is ranked 0.876. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of American Journal of Cardiovascular Drugs by Year


Year SJR
2025/2026 Coming Soon
2024 0.876
2023 0.79
2022 0.841
2021 1.010
2020 1.063
2019 0.854
2018 0.903
2017 0.951
2016 0.927
2015 0.920
2014 0.992

Ranking of American Journal of Cardiovascular Drugs by Year


Year Ranking
2025/2026 Coming Soon
2024 5925
2023 6332
2022 5546
2021 4040
2020 3987
2019 5437
2018 5003
2017 4667
2016 4876
2015 4962
2014 4385

American Journal of Cardiovascular Drugs Publisher


Table Setting

American Journal of Cardiovascular Drugs is published by . It's publishing house is located in Switzerland. Coverage history of this journal is as following: 2001-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of American Journal of Cardiovascular Drugs is Am. J. Cardiovasc. Drugs. This abbreviation ('Am. J. Cardiovasc. Drugs') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in American Journal of Cardiovascular Drugs


If your research field is/are related to Cardiology and Cardiovascular Medicine (Q2); Medicine (miscellaneous) (Q2); Pharmacology (medical) (Q2), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the American Journal of Cardiovascular Drugs?

American Journal of Cardiovascular Drugs latest impact IF is 2.80. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 3.56 (2021) and 2.40 (2018), respectively, in the last 11 years. Moreover, its average IS is 2.81 in the previous 11 years.


What's the SCImago Journal Rank (SJR) of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs has an SJR (SCImago Journal Rank) of 0.876, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 1.063 in 2020 and the lowest being 0.79 in 2023. Furthermore, the average SJR of the American Journal of Cardiovascular Drugs over the previous 11-year period stands at 2.81.


What's the latest h-index of the American Journal of Cardiovascular Drugs?

The latest h-index of the American Journal of Cardiovascular Drugs is 63.


Who's the publisher of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs is published by the , with its country of publication being the Switzerland.


What's the current ranking of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs is currently ranked 5925 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 3987 in 2020 and its lowest position of 6332 in 2023.


What's the abbreviation or short name for the American Journal of Cardiovascular Drugs?

The standard ISO4 abbreviation for the American Journal of Cardiovascular Drugs is Am. J. Cardiovasc. Drugs.


Is the "American Journal of Cardiovascular Drugs" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

American Journal of Cardiovascular Drugs is classified as a journal that the publishes.


What's the scope or major areas of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs encompasses the following areas:

  • Cardiology and Cardiovascular Medicine
  • Medicine (miscellaneous)
  • Pharmacology (medical)

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs is assigned the following International Standard Serial Numbers (ISSN): 11753277, 1179187X.


What's the best quartile of the American Journal of Cardiovascular Drugs?

The best quartile for the American Journal of Cardiovascular Drugs is Q2 (2024).


What's the coverage history of the American Journal of Cardiovascular Drugs?

The American Journal of Cardiovascular Drugs coverage history can be summarized as follows: 2001-2025.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Journal of Business Economics and Management journal 9811 Vilnius Gediminas Technical University 55 2.84
Journal of Field Archaeology journal 7683 Maney Publishing 48 1.85
Proceedings of the Spring Technical Conference of the ASME Internal Combustion Engine Division conference and proceedings 17477 16 0.00
Clinical Medicine and Research journal 14921 Marshfield Clinic 64 1.25
Business Strategy Review journal 31512 Wiley-Blackwell Publishing Ltd 33 0.04
Materials Research journal 15597 Universidade Federal de Sao Carlos 75 1.40
Journal, Indian Academy of Clinical Medicine journal 28559 Indian Academy of Clinical Medicine 16 0.10
Rinsan Shikenj Oha/Journal of the Hokkaido Forest Products Research Institute journal 29148 Hoikkaido Forest Products Research Institute 4 0.00
Indian Phytopathology journal 16772 Springer 20 0.91
Proceedings of the International Semiconductor Conference, CAS conference and proceedings 25734 Institute of Electrical and Electronics Engineers Inc. 16 0.00

Check complete list




Year wise Impact Score (IS) of American Journal of Cardiovascular Drugs

Impact Score Table

Year Impact Score (IS)
2025/2026 Coming Soon
2024 2.80
2023 2.66
2022 3.12
2021 3.56
2020 2.86
2019 2.60
2018 2.40
2017 2.85
2016 2.98
2015 2.49
2014 2.60



Top Journals/Conferences in Cardiology and Cardiovascular Medicine

Nature Reviews Cardiology
Nature Research | United Kingdom

Journal of the American College of Cardiology
Elsevier Inc. | United States

Circulation
Lippincott Williams and Wilkins | United States

JAMA Cardiology
American Medical Association | United States

European Journal of Heart Failure
John Wiley and Sons Ltd | United Kingdom

JACC: Cardiovascular Imaging
Elsevier Inc. | United States

JACC: Heart Failure
Elsevier Inc. | United States

European Heart Journal
Oxford University Press | United Kingdom

Circulation Research
Lippincott Williams and Wilkins | United States

Nature Cardiovascular Research
Springer | Germany

See All

Top Journals/Conferences in Medicine (miscellaneous)

MMWR Recommendations and Reports
Centers for Disease Control and Prevention (CDC) | United States

Nature Reviews Drug Discovery
Nature Research | United Kingdom

New England Journal of Medicine
Massachussetts Medical Society | United States

Annals of Oncology
Elsevier Ltd | United Kingdom

Nature Medicine
Nature Research | United Kingdom

Nature Reviews Disease Primers
Nature Publishing Group | United Kingdom

Nature Reviews Immunology
Nature Research | United Kingdom

Nature Reviews Methods Primers
Springer Nature | United Kingdom

Annual Review of Pathology: Mechanisms of Disease
Annual Reviews Inc. | United States

Physiological Reviews
American Physiological Society | United States

See All

Top Journals/Conferences in Pharmacology (medical)

Drug Resistance Updates
Churchill Livingstone | United Kingdom

Pharmacology and Therapeutics
Elsevier Inc. | United States

Drugs
| Switzerland

Journal of Biomedical Science
BioMed Central Ltd | United Kingdom

npj Breast Cancer
Nature Publishing Group | United Kingdom

Alimentary Pharmacology and Therapeutics
John Wiley and Sons Inc | United Kingdom

American Journal of Transplantation
Elsevier B.V. | Netherlands

Acta Pharmacologica Sinica
Springer Nature | United Kingdom

BioDrugs
| Switzerland

npj Vaccines
Nature Publishing Group | United Kingdom

See All